ALX Oncology Holdings Inc.
NASDAQ: ALXO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason Lettmann
- Employees
- 43
- Headquarters
- South San Francisco, United States
- IPO year
- 2020
- Market cap
- $240.9M
- Website
- https://www.alxoncology.com
Loading ALXO…
Loading profile data…Frequently asked questions about ALXO
What does ALX Oncology Holdings Inc. (ALXO) do?
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical stu...
Where does ALXO trade?
ALX Oncology Holdings Inc. (ALXO) trades on the NASDAQ.
What sector is ALXO in?
ALX Oncology Holdings Inc. (ALXO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ALX Oncology Holdings Inc.?
Jason Lettmann is the chief executive officer of ALX Oncology Holdings Inc. (ALXO).
Where is ALX Oncology Holdings Inc. headquartered?
ALX Oncology Holdings Inc. is headquartered in United States.
Does ALXO pay a dividend?
ALX Oncology Holdings Inc. (ALXO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALXO go public?
ALX Oncology Holdings Inc. (ALXO) completed its initial public offering in 2020.